Bellevue Group AG Decreases Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Bellevue Group AG lessened its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 95.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 19,046 shares of the company’s stock after selling 425,358 shares during the period. Bellevue Group AG’s holdings in Apellis Pharmaceuticals were worth $549,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. HighVista Strategies LLC increased its holdings in Apellis Pharmaceuticals by 4.1% in the 2nd quarter. HighVista Strategies LLC now owns 7,566 shares of the company’s stock valued at $290,000 after purchasing an additional 300 shares in the last quarter. Amalgamated Bank boosted its position in shares of Apellis Pharmaceuticals by 5.4% in the second quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock worth $268,000 after buying an additional 359 shares during the period. Simplicity Wealth LLC grew its stake in shares of Apellis Pharmaceuticals by 0.6% in the second quarter. Simplicity Wealth LLC now owns 78,746 shares of the company’s stock valued at $3,021,000 after buying an additional 499 shares in the last quarter. KBC Group NV raised its holdings in shares of Apellis Pharmaceuticals by 34.8% during the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after buying an additional 679 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Apellis Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after acquiring an additional 781 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the sale, the director now directly owns 100,000 shares of the company’s stock, valued at $3,623,000. This trade represents a 27.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 6.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on APLS shares. JPMorgan Chase & Co. lowered their price objective on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a research report on Friday, September 13th. Morgan Stanley assumed coverage on shares of Apellis Pharmaceuticals in a report on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price target for the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $25.00 price objective on shares of Apellis Pharmaceuticals in a report on Monday, November 4th. Citigroup lowered their target price on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Evercore ISI upgraded Apellis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, October 31st. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.94.

Apellis Pharmaceuticals Stock Performance

Shares of APLS opened at $33.93 on Monday. The stock has a market capitalization of $4.22 billion, a PE ratio of -16.71 and a beta of 0.87. The business’s fifty day moving average price is $28.72 and its 200 day moving average price is $35.25. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a 12-month low of $24.34 and a 12-month high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same quarter in the previous year, the business posted ($1.17) earnings per share. The company’s quarterly revenue was up 78.3% compared to the same quarter last year. Equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.72 EPS for the current year.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).